Medicare beneficiaries enrolled in standard Part D drug plans will pay up to $700 out of pocket before coverage kicks in starting in 2027, an $85 jump from the $615 cap in effect for 2026. The Centers for Medicare and Medicaid Services (CMS) confirmed the new figure in its cost threshold announcement for plan years ending in 2027, tying the increase to updated parameters in the annual Rate Announcement. For enrollees without low-income subsidies who rely on prescription medications, the higher deductible means a larger upfront bill at the pharmacy counter before their plan begins sharing costs.
Why the $85 Part D Deductible Jump Hits Beneficiaries Now
Under the current benefit structure, enrollees in standard Part D plans pay 100 percent of gross covered prescription drug costs until the annual deductible is met, according to CMS program instructions for the 2026 redesign. That threshold sits at $615 for 2026, a ceiling that no Medicare drug plan may exceed. The 2027 increase to $700 widens the gap between what beneficiaries spend before insurance applies and what many can comfortably afford on fixed incomes.
The timing matters because the deductible is the first cost-sharing hurdle most enrollees encounter each year. Beneficiaries who take brand-name medications or multiple maintenance drugs often meet the deductible within the first few months, meaning the entire $85 increase will be felt quickly. For people with modest prescription needs, the higher cap may function more like a de facto premium increase: they might never reach the deductible, but they must still weigh whether the plan’s potential protection later in the year is worth higher early-year exposure.
Not every plan charges the maximum. Some Part D sponsors already set their deductibles at zero or well below the allowed limit, a competitive tactic designed to attract enrollees who fill prescriptions early in the calendar year. As the standard amount rises, plans that hold their deductibles below $700 could gain a recruiting edge among beneficiaries shopping during the annual enrollment period. Whether that advantage translates into measurably faster enrollment growth among non-subsidized members is an open question. CMS has not published plan-level projections showing how many sponsors intend to adopt the full $700 or undercut it, and no official modeling ties lower deductibles to enrollment gains in a direct, quantified way.
For low-income beneficiaries who qualify for extra help, the deductible change may have less direct impact because subsidies can significantly reduce or eliminate upfront costs. However, the higher cap still shapes the overall market design, influencing how plans balance deductibles, premiums, and copayments for all enrollees. Beneficiaries who fall just above subsidy thresholds may feel the increase most acutely, as they pay full cost sharing without the cushion of income-based assistance.
CMS Documents Behind the $700 Threshold
The $700 figure appears in the CMS Retiree Drug Subsidy announcement on cost thresholds, which states that the 2027 cost threshold aligns with the standard deductible amount published in the Rate Announcement tables. That alignment means employer-sponsored retiree plans and standalone Part D sponsors are working from the same baseline when structuring benefits for the coming contract year. When CMS adjusts these parameters, it effectively resets the starting point for how much risk plans can shift to enrollees at the front end of coverage.
The 2026 comparison point of $615 on Medicare.gov also notes that some plans carry no deductible at all. CMS separately confirmed the $615 figure in its Final CY 2026 Part D Redesign Program Instructions, specifying that the enrollee bears the full cost of covered drugs until that amount is reached. Together, these records establish a clear year-over-year increase of $85, or roughly 13.8 percent, in the maximum standard deductible that plans may charge.
The broader policy framework arrives through CMS rulemaking for upcoming contract years, which the agency has described as aimed at strengthening accountability and long-term program sustainability. While those regulations address topics such as marketing standards and quality measurement, the deductible parameters flow through the annual rate-setting process that underpins Part D financing. In practice, the higher deductible gives plans more room to keep premiums stable or moderate other forms of cost sharing, but it does so by shifting more initial costs to beneficiaries.
For people evaluating coverage options, the new $700 ceiling underscores the importance of looking beyond premiums alone. During open enrollment, beneficiaries will need to compare deductibles, drug tier structures, and pharmacy networks to understand how quickly they might hit the deductible and what they will pay afterward. The CMS source documents make clear that while $700 is the maximum standard deductible, individual plan designs can and do vary, leaving room for consumers to seek out options that better match their medication needs and budgets.
Free tool for readers: Built for Americans 55 to 80: a free, plain-English retirement check. See your Retirement Safety Score — your 0–100 number and a few steps — in about five minutes, no account needed.
